Weekly Recap: Eye-product halt at Assam plant and 32% Q2 profit fall
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) was ordered by India’s regulator to halt production, sales and distribution of eye products made at its Assam plant over quality system failures.…
Attributed summary
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) was ordered by India’s regulator to halt production, sales and distribution of eye products made at its Assam plant over quality system failures. Second-quarter profit fell 32% year over year to ₹1,988.5 crore, including a one-time ₹1,269 crore…
Read the original report — TradingView
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
